Core Viewpoint - Ultragenyx Pharmaceutical's stock plummeted over 42% in pre-market trading following the announcement that its investigational drug for a specific genetic bone disease failed to meet primary efficacy endpoints in late-stage clinical trials [1] Company Summary - The stock price of Ultragenyx Pharmaceutical (RARE.US) fell to $19.69 as of the latest report [1] - The failure of the drug in clinical trials represents a significant setback for the company, impacting investor confidence and market valuation [1]

Core Viewpoint - Ultragenyx Pharmaceutical's stock price plummeted over 42% to $19.69 following the announcement that its investigational drug for a specific genetic bone disease did not meet its primary efficacy endpoint in late-stage clinical trials [1] Group 1 - The stock price of Ultragenyx Pharmaceutical (RARE.US) experienced a significant decline, dropping more than 42% [1] - As of the report, the stock was trading at $19.69 [1] - The decline was triggered by the failure of a key investigational drug in late-stage clinical trials [1]

Core Viewpoint - Ultragenyx Pharmaceutical announced that its investigational drug for a specific genetic bone disease did not meet the primary efficacy endpoint in late-stage clinical trials [1] Group 1 - The investigational drug is aimed at treating a specific genetic bone disease [1] - The announcement was made on a Monday [1] - The failure to meet the primary efficacy endpoint occurred during late-stage clinical trials [1]